Fairvalue-Calculator Fairvalue-Calculator
EN DE

Interpace Biosciences, Inc (IDXG) Fair Value & Analysis

Healthcare · US · Market cap $46.2M

Price$1.70
Fair Value$3.63
Upside+113.5%
Quality95/100
Evidence: High Range $2.72 – $4.54

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Interpace Biosciences, Inc (IDXG) currently trades at $1.70, while our model-based Fair Value estimate is $3.63 — implying the stock looks roughly 113.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -96% Danaher Corporation (DHR) -52% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -66% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -54%

Frequently asked questions

Is Interpace Biosciences, Inc (IDXG) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.63 versus a price of $1.70 — about +114% (undervalued). Model-based estimate, not financial advice.
What is the fair value of IDXG?
Our 21-model fair value for Interpace Biosciences, Inc is $3.63 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.70.
What is the quality score of IDXG?
Interpace Biosciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.